Isotechnika partner nears end of patient recruitment

Isotechnika Pharma (TSX:ISA) said its partner, Lux Biosciences, expects to complete patient recruitment of its continuing Phase 3 trial of Luveniq (voclosporin) in North America for the treatment of non-infectious uveitis in early 2012. Lux also has decided to modify its European regulatory strategy by withdrawing its application for marketing authorization of Luveniq for the [...]

Isotechnika partner starts uveitis Phase 3 trial

Isotechnika Pharma’s (TSX: ISA) partner Lux Biosciences has begun an additional Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. The six-month study will involve 150 patients in North America and Europe with active non-infectious intermediate, posterior, or pan-uveitis. Lux is conducting this additional [...]

Lux-Isotechnika get complete response letter from FDA

Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has received a complete response letter from the FDA about its new drug application for voclosporin in the treatment of non-infectious uveitis, involving the intermediate or posterior segments of the eye. The FDA has requested additional information and recommended that an additional clinical trial be conducted in order to [...]